Preferred Label : velpatasvir;
UNII : KCU0C7RS7Z;
Origin ID : C000604171;
UMLS CUI : C4079582;
ATC code(s)
- CISMeF manual mappings
- MeSH term(s) associated for indexing
- Pharmacological action(s)
- Record concept(s)
- See also (suggested by CISMeF)
- Semantic type(s)
- UMLS correspondences (same concept)
https://www.has-sante.fr/jcms/p_3337733/fr/epclusa-sofosbuvir/-velpatasvir-vhc
2022
false
false
false
France
evaluation of the transparency committee
velpatasvir
hepacivirus
Epclusa
velpatasvir
---
https://www.has-sante.fr/jcms/p_3337938/fr/vosevi-sofosbuvir/-voxilaprevir/-velpatasvir-vhc
2022
false
false
false
France
evaluation of the transparency committee
velpatasvir
velpatasvir
hepacivirus
Vosevi
---
https://www.has-sante.fr/jcms/p_3299655/fr/epclusa-sofosbuvir/-velpatasvir
2021
false
false
false
France
evaluation of the transparency committee
velpatasvir
velpatasvir
Epclusa
registries
outcome studies
Outcome Assessment, Health Care
resulting in
---
https://www.has-sante.fr/jcms/p_3299679/fr/vosevi-sofosbuvir/-voxilaprevir/-velpatasvir
2021
false
false
false
France
evaluation of the transparency committee
registries
velpatasvir
velpatasvir
Vosevi
resulting in
outcome studies
Outcome Assessment, Health Care
---
https://www.has-sante.fr/jcms/p_3152667/fr/epclusa
2020
false
false
false
France
Sofosbuvir
velpatasvir
sofosbuvir-velpatasvir drug combination
sofosbuvir and velpatasvir
hepatitis C, chronic
evaluation of the transparency committee
Epclusa
carbamates
Heterocyclic Compounds, 4 or More Rings
drug combinations
---
https://www.has-sante.fr/jcms/p_3152658/fr/vosevi
2020
false
false
false
France
sofosbuvir, velpatasvir and voxilaprevir
drug combinations
Sofosbuvir
velpatasvir
voxilaprevir
adult
administration, oral
treatment outcome
insurance, health, reimbursement
hepatitis C, chronic
antiviral agents
evaluation of the transparency committee
carbamates
Heterocyclic Compounds, 4 or More Rings
sulfonamides
macrocyclic compounds
sofosbuvir velpatasvir voxilaprevir drug combination
---
https://www.ema.europa.eu/medicines/human/EPAR/Vosevi
2017
false
false
false
United Kingdom
French
English
syndication feed
summary of product characteristics
package leaflet
sulfonamides
sulfonamides
macrocyclic compounds
macrocyclic compounds
Sofosbuvir
velpatasvir
carbamates
Heterocyclic Compounds, 4 or More Rings
drug approval
europe
treatment outcome
product surveillance, postmarketing
administration, oral
hepatitis C, chronic
antiviral agents
antiviral agents
adult
drug interactions
pregnancy
breast feeding
NS-5 protein, hepatitis C virus
NS-5a protein, hepatitis C virus
Substance with Hepatitis C virus NS3/4A protease inhibitor mechanism of action (substance)
viral nonstructural proteins
serine proteases
drug evaluation, preclinical
sofosbuvir, velpatasvir and voxilaprevir
voxilaprevir
voxilaprevir
NS3-4A serine protease, Hepatitis C virus
Sofosbuvir
velpatasvir
carbamates
Heterocyclic Compounds, 4 or More Rings
drug combinations
sofosbuvir velpatasvir voxilaprevir drug combination
---
https://www.has-sante.fr/portail/jcms/c_2817995/fr/vosevi
2017
false
false
false
France
French
sulfonamides
sulfonamides
macrocyclic compounds
macrocyclic compounds
Sofosbuvir
velpatasvir
carbamates
Heterocyclic Compounds, 4 or More Rings
treatment outcome
administration, oral
hepatitis C, chronic
antiviral agents
antiviral agents
adult
NS-5 protein, hepatitis C virus
NS-5a protein, hepatitis C virus
Substance with Hepatitis C virus NS3/4A protease inhibitor mechanism of action (substance)
viral nonstructural proteins
serine proteases
insurance, health, reimbursement
evaluation of the transparency committee
sofosbuvir, velpatasvir and voxilaprevir
voxilaprevir
voxilaprevir
Sofosbuvir
velpatasvir
carbamates
Heterocyclic Compounds, 4 or More Rings
drug combinations
sofosbuvir velpatasvir voxilaprevir drug combination
---
http://www.has-sante.fr/portail/jcms/c_2724396/fr/epclusa
http://www.has-sante.fr/portail/jcms/c_2724396/fr/epclusa-sofosbuvir/velpatasvir-association-fixe-d-antiviraux-a-action-directe
2016
false
false
false
France
French
evaluation of the transparency committee
insurance, health, reimbursement
treatment outcome
drug combinations
Sofosbuvir
Sofosbuvir
administration, oral
hepatitis C, chronic
antiviral agents
antiviral agents
velpatasvir
velpatasvir
hepatitis C, chronic
adult
guidelines for drug use
sofosbuvir-velpatasvir drug combination
sofosbuvir-velpatasvir drug combination
sofosbuvir and velpatasvir
carbamates
Heterocyclic Compounds, 4 or More Rings
carbamates
Heterocyclic Compounds, 4 or More Rings
drug combinations
drug combinations
---
https://www.ema.europa.eu/medicines/human/EPAR/Epclusa
2016
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
velpatasvir
velpatasvir
drug combinations
Sofosbuvir
Sofosbuvir
antiviral agents
antiviral agents
pregnancy
breast feeding
drug interactions
hepatitis C, chronic
adult
administration, oral
drug therapy, combination
NS-5a protein, hepatitis C virus
enzyme inhibitors
enzyme inhibitors
RNA-Dependent RNA Polymerase
product surveillance, postmarketing
aged
drug evaluation, preclinical
sofosbuvir-velpatasvir drug combination
sofosbuvir and velpatasvir
NS-5 protein, hepatitis C virus
viral nonstructural proteins
carbamates
Heterocyclic Compounds, 4 or More Rings
carbamates
Heterocyclic Compounds, 4 or More Rings
Sofosbuvir
carbamates
Heterocyclic Compounds, 4 or More Rings
---
